Is Bioatla Inc (BCAB) overvalued? · $5.9M cap
Bioatla Inc (BCAB) is a biotechnology company listed on NASDAQ.
This page asks whether Bioatla Inc (BCAB) looks expensive on cached numbers — not a short thesis.
Latest reported BCAB revenue for 2023-09-30 was $0. Net income was -$33.3M. BCAB currently screens at market cap $5.9M.
BCAB currently screens at market cap $5.9M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BCAB 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BCAB stock page for the full model, not this heading.
Not investment advice.